Cargando…

Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?

Detalles Bibliográficos
Autores principales:	Boyd, Kathleen A, Briggs, Andrew H, Paul, Jim, Iveson, Tim, Midgely, Rachel, Harkin, Andrea, Bates, Gaynor, Alexander, Laura, Cassidy, Jim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287757/ http://dx.doi.org/10.1186/1745-6215-12-S1-A41

Ejemplares similares

Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study
por: Paul, Jim, et al.
Publicado: (2011)

Can we stop malaria parasites in the skin?
por: Douglas, Ross, et al.
Publicado: (2014)

Where is the family when we work with adult patients? An eating disorders perspective
por: Metres, Marie-Louise, et al.
Publicado: (2013)

To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery?
por: van Duren, Bernard H, et al.
Publicado: (2021)

Treatment-as-prevention: stopping the epidemic of HIV
por: Williams, B
Publicado: (2010)

P02 When should we stop the antiresorptive medications in patients with osteoporosis?
por: Mohareb, Marwa, et al.
Publicado: (2023)

Are Daily Sedation Stops Safe in a Medical Icu?
por: Debue, AS, et al.
Publicado: (2015)

When the cycling stopped...
Publicado: (1984)

Beyond total treatment effects in RCTs: why we need to measure outcomes at baseline when investigating mediation
por: Landau, Sabine, et al.
Publicado: (2015)

The deprescribing rainbow: a conceptual framework highlighting the importance of patient context when stopping medication in older people
por: Todd, Adam, et al.
Publicado: (2018)

Prediction of Noninvasive Ventilation Failure in COVID-19 Patients: When Shall We Stop?
por: Neves da Silva, Luís, et al.
Publicado: (2022)

Can we reduce bias in open-label trials when blinded outcome assessment is not possible? An example from the trigger trial
por: Kahan, Brennan, et al.
Publicado: (2015)

Stop turning a blind eye!
por: Reekers, Jim A.
Publicado: (2021)

When to start and when to stop antifibrotic therapies
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2017)

Search for Long Lived Particles that Stop in CMS
por: Brooke, Jim
Publicado: (2010)

Should We Stop Collecting the Preoperative Autologous Blood before Bone Marrow Harvest?
por: Lysák, Daniel, et al.
Publicado: (2021)

Stopping screening, when and how?
por: Hugosson, Jonas
Publicado: (2018)

When Should Statins Be Stopped?
por: Bibi, Mário, et al.
Publicado: (2021)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
por: Iveson, Timothy J, et al.
Publicado: (2018)

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
por: Robles-Zurita, José, et al.
Publicado: (2018)

Designing and analysing feasibility studies of complex interventions: challenges related to assessing stop/go criteria
por: Collinson, Michelle, et al.
Publicado: (2013)

Rationale for adjuvant measures in musculoskeletal diseases
por: Gast, Ulf
Publicado: (2013)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Are we getting the whole picture? Measuring outcomes using routinely collected data in long term follow-up: an example from BB:2-6
por: Cannings-John, Rebecca, et al.
Publicado: (2015)

Factors involved in the development of the metabolic syndrome. We are what we eat and what we are eating
por: Masuzaki, Hiroaki
Publicado: (2013)

What could stop us and when
por: Bottura, L, et al.
Publicado: (2014)

Stopping Antiepileptic Drugs: When and Why?
por: Hixson, John D.
Publicado: (2010)

Evidence for capacity sharing when stopping
por: Verbruggen, Frederick, et al.
Publicado: (2015)

When to stop propranolol for infantile hemangioma
por: Chang, Lei, et al.
Publicado: (2017)

What happens when the stories stop?
por: Westgarth, David
Publicado: (2021)

When in a Hole, Stop Digging
por: Potters, Louis
Publicado: (2021)

Stopping epidemics when and where they occur
por: Torreele, Els, et al.
Publicado: (2023)

Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
por: Blinman, Prunella, et al.
Publicado: (2020)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

Controversies in the hormonal adjuvant therapy of postmenopausal patients
por: Dowsett, M
Publicado: (2009)

Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009)

BRCA1 transcriptionally regulates genes associated with the basal breast cancer phenotype
por: Quinn, JE, et al.
Publicado: (2006)

The economics of stop-and-go epidemic control
por: Gros, Claudius, et al.
Publicado: (2022)

Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
por: Lee, J.J.X., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mn4a2q9u09q9j75di922a0nua1